462 related articles for article (PubMed ID: 34038797)
1. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
2. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
3. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer.
Nesbitt H; Sheng Y; Kamila S; Logan K; Thomas K; Callan B; Taylor MA; Love M; O'Rourke D; Kelly P; Beguin E; Stride E; McHale AP; Callan JF
J Control Release; 2018 Jun; 279():8-16. PubMed ID: 29653222
[TBL] [Abstract][Full Text] [Related]
5. The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Higuchi T; Kawaguchi K; Miyake K; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Nelson SD; Dry SM; Li Y; Chawla SP; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Mar; 111():835-840. PubMed ID: 30616082
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
Shimamoto N; Ito M; Chiba M; Honma S; Imazu H; Sumiyama K
Hepatobiliary Pancreat Dis Int; 2020 Oct; 19(5):478-485. PubMed ID: 32265136
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Dong S; Guo Y; Duan Y; Li Z; Wang C; Niu L; Wang N; Ma M; Shi Y; Zhang M
Anticancer Drugs; 2018 Aug; 29(7):637-645. PubMed ID: 29846247
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-Phospholipid Complex Loaded Lipid Nanoparticles for Improving Drug Loading, Stability, and Efficacy against Pancreatic Cancer.
Dora CP; Kushwah V; Yadav V; Kuche K; Jain S
Mol Pharm; 2024 Jun; 21(6):2699-2712. PubMed ID: 38747900
[TBL] [Abstract][Full Text] [Related]
11. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
[TBL] [Abstract][Full Text] [Related]
13. An ultrasound responsive microbubble-liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic cancer.
Gao J; Nesbitt H; Logan K; Burnett K; White B; Jack IG; Taylor MA; Love M; Callan B; McHale AP; Callan JF
Eur J Pharm Biopharm; 2020 Dec; 157():233-240. PubMed ID: 33222772
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
[TBL] [Abstract][Full Text] [Related]
15. Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and Rose Bengal.
Logan K; Foglietta F; Nesbitt H; Sheng Y; McKaig T; Kamila S; Gao J; Nomikou N; Callan B; McHale AP; Callan JF
Eur J Pharm Biopharm; 2019 Jun; 139():224-231. PubMed ID: 30959180
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Mizutani Y; Iida T; Ohno E; Ishikawa T; Kinoshita F; Kuwatsuka Y; Imai M; Shimizu S; Tsuruta T; Enomoto A; Kawashima H; Fujishiro M
BMC Cancer; 2022 Feb; 22(1):205. PubMed ID: 35209871
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Vogel A; Römmler-Zehrer J; Li JS; McGovern D; Romano A; Stahl M
BMC Cancer; 2016 Oct; 16(1):817. PubMed ID: 27769210
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Hasegawa R; Okuwaki K; Kida M; Yamauchi H; Kawaguchi Y; Matsumoto T; Kaneko T; Miyata E; Uehara K; Iwai T; Watanabe M; Kurosu T; Imaizumi H; Ohno T; Koizumi W
Int J Clin Oncol; 2019 Dec; 24(12):1574-1581. PubMed ID: 31309381
[TBL] [Abstract][Full Text] [Related]
20. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D
Br J Cancer; 2016 Jul; 115(2):188-94. PubMed ID: 27351217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
